NovoCure Limited
NVCR
$11.19
-$0.49-4.20%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.81% | 5.62% | 11.91% | 20.54% | 21.81% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.81% | 5.62% | 11.91% | 20.54% | 21.81% |
| Cost of Revenue | 26.45% | 19.67% | 14.34% | 2.20% | 10.22% |
| Gross Profit | 2.30% | 1.41% | 11.12% | 26.26% | 25.72% |
| SG&A Expenses | 4.54% | 7.10% | 6.15% | 47.67% | 0.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.57% | 7.82% | 7.13% | 25.07% | 0.87% |
| Operating Income | -12.24% | -17.69% | 8.80% | -38.55% | 44.90% |
| Income Before Tax | -39.09% | -53.90% | 4.26% | -43.27% | 55.24% |
| Income Tax Expenses | -19.33% | -51.53% | -43.47% | 25.41% | 611.40% |
| Earnings from Continuing Operations | -21.92% | -20.27% | 11.46% | -40.02% | 38.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.92% | -20.27% | 11.46% | -40.02% | 38.22% |
| EBIT | -12.24% | -17.69% | 8.80% | -38.55% | 44.90% |
| EBITDA | -9.19% | -17.43% | 10.76% | -39.18% | 46.55% |
| EPS Basic | -17.92% | -16.10% | 13.87% | -38.08% | 39.07% |
| Normalized Basic EPS | -34.59% | -41.44% | 6.89% | -37.87% | 55.86% |
| EPS Diluted | -17.92% | -16.10% | 13.87% | -38.10% | 39.07% |
| Normalized Diluted EPS | -34.59% | -41.44% | 6.89% | -37.87% | 55.86% |
| Average Basic Shares Outstanding | 3.38% | 3.60% | 2.81% | 1.39% | 1.38% |
| Average Diluted Shares Outstanding | 3.38% | 3.60% | 2.81% | 1.39% | 1.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |